TY  - GEN
AU  - Mosenzon,O
AU  - Raz,I
AU  - Scirica,B M
AU  - Hirshberg,B
AU  - Stahre,C I
AU  - Steg,P G
AU  - Davidson,J
AU  - Ohman,P
AU  - Price,D L
AU  - Frederich,B
AU  - Udell,J A
AU  - Braunwald,E
AU  - Bhatt,D L
TI  - Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial
SN  - 1520-7560
PY  - 2013///1101
KW  - Adamantane
KW  - adverse effects
KW  - Aged
KW  - Biomarkers
KW  - blood
KW  - Body Mass Index
KW  - Cardiovascular Diseases
KW  - chemically induced
KW  - Diabetes Mellitus, Type 2
KW  - Diabetic Angiopathies
KW  - epidemiology
KW  - Diabetic Nephropathies
KW  - Dipeptides
KW  - Dipeptidyl-Peptidase IV Inhibitors
KW  - Drug Therapy, Combination
KW  - Female
KW  - Humans
KW  - Hyperglycemia
KW  - Hypoglycemic Agents
KW  - Insulin Resistance
KW  - Male
KW  - Middle Aged
KW  - Overweight
KW  - complications
KW  - Prevalence
KW  - Risk Factors
KW  - Severity of Illness Index
N1  - Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1002/dmrr.2413
ER  -